3-substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 17, 1997, Pages 2307-2312

  Reiter, Lawrence A ^a   Melvín Jr , Lawrence S ^a   Crean, Geraldine L ^a   Showell, Henry J ^a   Koch, Kevin ^a   Biggers, Michael S ^a   Cheng, John B ^a   Breslow, Robbin ^a   Conklyn, Maryrose J ^a   Farrell, Cathy A ^a   Hada, William A ^a   Laird, Ellen R ^a   Martin, John J ^a   Miller, G Todd ^a   Pillar, Joanne S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST;

ARTICLE; CHEMICAL MODIFICATION; DIASTEREOISOMER; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NEUTROPHIL CHEMOTAXIS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 0030885418     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00414-9     Document Type: Article

References (18)

1. 4's relationship to disease and the search for therapeutically useful antagonists see: Perez, H. D. In Chemoattractant Ligands Their Recept.; Horuk, R., Ed.; CRC: Boca Raton, FL 1996; pp 261-268. Brooks, C. D. W.; Summers, J. B. J. Med Chem. 1996, 39, 2629. Fretland, D. J.; Penning, T. D. Expert Opin. Ther. Pat. 1996, 6, 21. Sawyer, J. S. Expert Opin. Invest. Drugs 1996, 5, 73.
2. 4's relationship to disease and the search for therapeutically useful antagonists see: Perez, H. D. In Chemoattractant Ligands Their Recept.; Horuk, R., Ed.; CRC: Boca Raton, FL 1996; pp 261-268. Brooks, C. D. W.; Summers, J. B. J. Med Chem. 1996, 39, 2629. Fretland, D. J.; Penning, T. D. Expert Opin. Ther. Pat. 1996, 6, 21. Sawyer, J. S. Expert Opin. Invest. Drugs 1996, 5, 73.
3. 4's relationship to disease and the search for therapeutically useful antagonists see: Perez, H. D. In Chemoattractant Ligands Their Recept.; Horuk, R., Ed.; CRC: Boca Raton, FL 1996; pp 261-268. Brooks, C. D. W.; Summers, J. B. J. Med Chem. 1996, 39, 2629. Fretland, D. J.; Penning, T. D. Expert Opin. Ther. Pat. 1996, 6, 21. Sawyer, J. S. Expert Opin. Invest. Drugs 1996, 5, 73.
4. 4's relationship to disease and the search for therapeutically useful antagonists see: Perez, H. D. In Chemoattractant Ligands Their Recept.; Horuk, R., Ed.; CRC: Boca Raton, FL 1996; pp 261-268. Brooks, C. D. W.; Summers, J. B. J. Med Chem. 1996, 39, 2629. Fretland, D. J.; Penning, T. D. Expert Opin. Ther. Pat. 1996, 6, 21. Sawyer, J. S. Expert Opin. Invest. Drugs 1996, 5, 73.
5. Showell, H. J.; Breslow, R.; Farrell, C. A. unpublished observations.
6. Crean, G. L.; Shay, A.; Connolly, T. unpublished observations. See Shay, A.; Connolly, T.; Smith, D. N.; Crean, G. L. Agents Actions 1989, 27, 361.
7. Crean, G. L.; Shay, A.; Connolly, T. unpublished observations. See Shay, A.; Connolly, T.; Smith, D. N.; Crean, G. L. Agents Actions 1989, 27, 361.
8. Koch, K.; Melvin, L. S., Jr.; Reiter, L. A.; Biggers, M. S.; Showell, H. J.; Griffiths, R. J.; Pettipher, E. R.; Cheng, J. B.; Milici, A. J.; Breslow, R.; Conklyn, M. J.; Smith, M. A.; Hackman, B. C.; Doherty, N. S.; Salter, E.; Farrell, C. A.; Schulte, G. J. Med. Chem. 1994, 37, 3197.
9. Cheng, J. B.; Cheng, E. I-P.; Kohi, F.; Townley, R. G. J. Pharmacol. Exp. Ther. 1986, 236, 1985.
10. Showell, H. J.; Pettipher, E. R.; Cheng, J. B.; Breslow, R.; Conklyn, M. J.; Farrell, C. A.; Hingorani, G. P.; Salter, E. D.; Hackman, B. C.; Wimberly, D. J.; Doherty, N. S.; Melvin, L. S., Jr.; Reiter, L. A.; Biggers, M. S.; Koch, K. J. Pharmacol. Exp. Ther. 1995, 273, 176.
11. Compounds 21 and 22 may display comparatively potent chemotactic activity by virtue of their being converted to 6 under the conditions of the assay. This possibility was not specifically examined.
12. Conformations for compounds 11, 26, 27, 37, 39, the 3,4-cis analog of 11, and the 4-deoxy analog of 6 were generated using a stochastic search method implemented in the Sybyl program (Tripos, Inc.; St. Louis, MO). For consistency, the substituent at the 7-position of each chromanol analogue was removed. Each conformer was optimized by ab initio methods using first the 3-21G and then the 6-31G(d) basis sets as implemented in the Spartan program (Wavefunction, Inc.; Irvine, CA).
13. Kobayashi, Y.; Shimazaki, T.; Kawajiri, K.; Shimizu, T.; Seyama, Y.; Sato, F. Biochim. Biophys. Acta 1994, 1215, 280.
14. Soyombo, O.; Spur, B. W.; Soh, C.; Lee, T. H. Eur. J. Biochem. 1993, 218, 59.
15. Leblanc, Y.; Fitzsimmons, B. J.; Charleson, S.; Alexander, P.; Evans, J. F.; Rokach, J. Prostaglandins 1987, 33, 617.
16. Cristol, J. P.; Provencal, B.; Borgeat, P.; Sirois, P. J. Pharmacol. Exp. Ther. 1988, 247, 1199.
17. Griffiths, R. J.; Pettipher, E. R.; Koch, K.; Farrell, C. A.; Breslow, R.; Conklyn, M. J.; Smith, M. A.; Hackman, B. C.; Wimberly, D. J.; Milici, A. J.; Scampoli, D. N.; Cheng, J. B.; Pillar, J. S.; Pazoles, C. J.; Doherty, N. S.; Melvin, L. S., Jr.; Reiter, L. A.; Biggers, M. S.; Falkner, F. C.; Mitchell, D. Y.; Liston, T. E.; Showell, H. J. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 517.
18. Liston, T. E.; Conklyn, M. J.; Houser, J.; Wilner, K. D.; Johnson, A.; Aspeloff, G.; Whitacre, C.; Showell, H. J. Brit. J. Clin. Pharm. in press.